Search

Displaying results 3981 - 3990 of 8700 in total
  1. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  2. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

  3. Drug

    J147

    go.drugbank.com/drugs/DB13957
    Experimental

    that impacts many pathways implicated in the pathogenesis of diabetic neuropathy. … [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  4. Drug

    Cytarabine

    go.drugbank.com/drugs/DB00987
    ApprovedInvestigational

    Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Alexan 100 mg/ml - Konzentrat zur Herstellung einer Infusionslösung
  5. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  6. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    Aceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]

    Categories: Cholinergic Receptor Agonist
  7. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  8. Target

    dTTP/UTP pyrophosphatase

    go.drugbank.com/bio_entities/BE0001527
    TargetBacillus subtilis (strain 168)

    May have a dual role in cell division arrest and in preventing the incorporation of modified nucleotides into cellular nucleic acids (PubMed:24210219).

    Synonyms: Septum formation protein Maf
  9. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

  10. Drug

    Benzoin

    go.drugbank.com/drugs/DB14020
    ApprovedWithdrawn

    Benzoin is an FDA-approved colour additive used for marking fruits and vegetables.